The Role of Targeted Therapy in Head and Neck Cancers

Dear Colleagues,

Head and neck cancers remain challenging to treat due to high recurrence rates and limited response to conventional therapies. Despite advanced knowledge of the underlying biology of the disease, there has been very little therapeutic development that has translated into improved survival rates for patients.

We are pleased to invite you to explore how a deeper understanding into drug mechanism-of-action, resistance, and patient responses to targeted therapies can shape future clinical oncology practice.

As conventional treatments such as chemoradiotherapy often fail and carry serious side-effects, targeted therapies represent a promising shift toward safe and effective personalized treatment strategies. This Special Issue aims to highlight advances in molecular profiling, biomarker discovery and patient stratification that are transforming approaches to head and neck cancer management.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but not limited to) the following: preclinical and clinical studies showcasing innovative therapeutic strategies such as antibody-drug conjugates, RNA-based therapeutics, small molecule inhibitors,  targeted drug delivery systems, and combination regimens involving targeted agents. Submissions may also focus on molecular profiling, biomarker discovery, and strategies to reduce treatment-related toxicity to better guide the clinical use of targeted therapies.

This is a unique opportunity to contribute meaningful work to a rapidly evolving field and help shape the future of head and neck cancer therapy. I look forward to receiving your contributions.

Dr. Rikki A.M. Brown
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.